Literature DB >> 17686382

The metabolic syndrome in hypertension: diagnostic and therapeutic implications.

Josep Redon1, Renata Cífková.   

Abstract

Arterial hypertension is often part of a larger constellation of anthropometric and metabolic abnormalities that includes abdominal (or visceral) obesity, characteristic dyslipidemia (low high-density lipoprotein cholesterol and high triglyceride levels), glucose intolerance, insulin resistance, and hyperuricemia. Using National Cholesterol Education Program Adult Treatment Panel III criteria, prevalence is higher than in the general population and the metabolic syndrome can be found in as many as one third of patients. Among hypertensives with metabolic syndrome, a high prevalence of hypertension-induced target-organ damage and a poor prognostic value has been described. Dietary advice and lifestyle changes should be strongly recommended and prompt pharmacologic treatment is required to control high blood pressure and to reduce risk. The impact of particular antihypertensive drugs on other components of the metabolic syndrome is an important clinical issue with consequences for the success of treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17686382     DOI: 10.1007/s11906-007-0056-9

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  49 in total

1.  Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity).

Authors:  Paul D Thompson; David Buchner; Ileana L Pina; Gary J Balady; Mark A Williams; Bess H Marcus; Kathy Berra; Steven N Blair; Fernando Costa; Barry Franklin; Gerald F Fletcher; Neil F Gordon; Russell R Pate; Beatriz L Rodriguez; Antronette K Yancey; Nanette K Wenger
Journal:  Circulation       Date:  2003-06-24       Impact factor: 29.690

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 3.  Obesity-associated hypertension: new insights into mechanisms.

Authors:  Kamal Rahmouni; Marcelo L G Correia; William G Haynes; Allyn L Mark
Journal:  Hypertension       Date:  2004-12-06       Impact factor: 10.190

4.  Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome: the Evaluation of Target Organ Damage in Hypertension study.

Authors:  Cesare Cuspidi; Stefano Meani; Veronica Fusi; Cristiana Valerio; Eleonora Catini; Carla Sala; Lorena Sampieri; Fabio Magrini; Alberto Zanchetti
Journal:  J Hypertens       Date:  2005-04       Impact factor: 4.844

5.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

6.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

7.  Effects of irbesartan on the growth and differentiation of adipocytes in obese zucker rats.

Authors:  Clara Di Filippo; Enrico Lampa; Elisabetta Tufariello; Pasquale Petronella; Fulvio Freda; Annalisa Capuano; Michele D'Amico
Journal:  Obes Res       Date:  2005-11

8.  Different impact of the metabolic syndrome on left ventricular structure and function in hypertensive men and women.

Authors:  Giuseppe Schillaci; Matteo Pirro; Giacomo Pucci; Massimo R Mannarino; Fabio Gemelli; Donatella Siepi; Gaetano Vaudo; Elmo Mannarino
Journal:  Hypertension       Date:  2006-04-03       Impact factor: 10.190

9.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

10.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

View more
  1 in total

Review 1.  Update on the metabolic syndrome: hypertension.

Authors:  Kristi Reynolds; Rachel P Wildman
Journal:  Curr Hypertens Rep       Date:  2009-04       Impact factor: 5.369

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.